Dapagliflozin in Chronic Kidney Disease
Yes, dapagliflozin tablets can and should be prescribed to patients with chronic kidney disease when eGFR is ≥25 mL/min/1.73 m², regardless of diabetes status, and should be continued even if eGFR later falls below 25 mL/min/1.73 m² until dialysis is required. 1, 2
Initiation Criteria
Dapagliflozin 10 mg once daily is strongly recommended for CKD patients when eGFR ≥25 mL/min/1.73 m². 3, 1 The 2024 BMJ guideline provides a strong recommendation (Grade 1A) for SGLT-2 inhibitor use in adults with CKD at very high risk of progression, and KDIGO 2022 specifically endorses dapagliflozin as one of three SGLT-2 inhibitors proven effective in this population. 3
Specific Indications by Risk Level:
Very high-risk CKD patients (rapid progression, advanced disease): Strong recommendation in favor—dapagliflozin reduces all-cause mortality by 48 per 1000 and kidney failure by 58 per 1000 over median 2.4 years. 3
High-risk CKD patients: Moderate certainty evidence shows reductions in all-cause mortality (24 fewer per 1000), cardiovascular mortality, non-fatal MI, and stroke. 3
Low-risk CKD patients: Weak recommendation in favor based on moderate certainty of small but important mortality and stroke reductions. 3
Dosing Strategy
The standard dose is 10 mg once daily for cardiovascular and kidney protection when eGFR ≥25 mL/min/1.73 m². 1, 2 This dose remains unchanged regardless of how low eGFR falls, provided the patient is not yet on dialysis. 1
Critical Distinction—Glycemic vs. Cardiorenal Indication:
Do NOT use dapagliflozin for glucose-lowering when eGFR <45 mL/min/1.73 m² because glycemic efficacy is markedly reduced. 1, 2 The FDA label explicitly states this limitation. 2
DO continue dapagliflozin 10 mg daily for cardiovascular and kidney protection even when eGFR is 25–45 mL/min/1.73 m², despite lack of glucose-lowering effect. 1 This is the most common pitfall—clinicians mistakenly stop the drug when eGFR falls below 45, losing critical cardiorenal benefits. 1
Continuation Principle
Once initiated, continue dapagliflozin even if eGFR falls below 25 mL/min/1.73 m²; stop only when dialysis or transplantation is required. 1, 2 The FDA label (2024) explicitly permits continuation below 25 mL/min/1.73 m² to reduce risk of eGFR decline, ESKD, cardiovascular death, and heart failure hospitalization. 2
Do NOT initiate dapagliflozin if eGFR is already <25 mL/min/1.73 m² or if the patient is on chronic dialysis. 1, 2
Expected Renal Effects & Monitoring
An initial eGFR decline of 2–5 mL/min/1.73 m² within the first 2–4 weeks is typical, reversible, and NOT a reason to stop therapy. 1 This hemodynamic dip reflects reduced intraglomerular pressure and is a marker of the drug's mechanism of action, not kidney injury. 1
Monitoring Protocol:
Re-measure eGFR and assess volume status 2–4 weeks after starting, then periodically. 1
After the early dip, eGFR usually stabilizes and the long-term decline slope is attenuated. 1 In the DAPA-CKD trial, dapagliflozin reduced the composite kidney endpoint by 44% (HR 0.56; 95% CI 0.45–0.68). 4
In stage 4 CKD (eGFR <30 mL/min/1.73 m²), dapagliflozin slowed eGFR decline by 1.23 mL/min/1.73 m² per year compared to placebo (P=0.005). 5
Pre-Initiation Assessment
Reduce concurrent diuretic dose by 30–50% in individuals at risk for hypovolemia before starting dapagliflozin. 1 This includes elderly patients, those with low systolic blood pressure, or those on loop diuretics. 1
If the patient is already meeting glycemic targets, lower insulin dose by ≈20% or decrease sulfonylurea dose to avoid hypoglycemia. 1
Check serum potassium and ensure it is within normal range prior to initiation. 1 Notably, dapagliflozin lowers the risk of hyperkalemia without causing hypokalemia, facilitating concurrent use of RAS inhibitors. 1
Safety Considerations
Monitor for genital mycotic infections, especially in women, and provide hygiene counseling. 1 These occur in approximately 6% of treated patients. 1
Educate patients on "sick-day" rules: hold dapagliflozin during acute illness with nausea, vomiting, diarrhea, or prolonged fasting to lower ketoacidosis risk. 1 The FDA label mandates withholding for at least 3 days before major surgery or procedures with prolonged fasting. 2
Temporarily hold dapagliflozin during severe acute illness with marked dehydration. 1
Common Pitfalls to Avoid
Do NOT discontinue dapagliflozin solely because of the early eGFR dip or because eGFR falls below 25 mL/min/1.73 m²; continue until dialysis is required. 1
Do NOT withhold dapagliflozin in patients with eGFR 25–44 mL/min/1.73 m² when the indication is CKD or heart failure, even though glycemic efficacy is minimal; cardiovascular and renal benefits persist. 1
Do NOT combine dapagliflozin with another SGLT-2 inhibitor; no additive benefit has been demonstrated. 1
Evidence in Advanced CKD
The DAPA-CKD trial enrolled 4,304 participants with eGFR 25–75 mL/min/1.73 m² and demonstrated consistent benefits across the entire eGFR range. 4 Among 624 patients with stage 4 CKD (eGFR <30), dapagliflozin reduced the primary composite endpoint by 27% (95% CI: -2% to 47%), with similar safety profile to those with higher eGFR. 5
Effects were consistent in patients with and without type 2 diabetes (HR 0.64 vs. 0.50; P-interaction=0.24). 6 Real-world data from OPTIMISE-CKD showed similar kidney protection across all albuminuria levels, including those with UACR <30 mg/g. 7
Special Populations
Dapagliflozin is NOT recommended for CKD patients with polycystic kidney disease or those requiring immunosuppressive therapy for kidney disease. 2 The FDA label explicitly excludes these populations because the drug is not expected to be effective. 2 Limited observational data in ADPKD patients (n=7) showed potential kidney function benefit when combined with RAS inhibitors, but kidney volume increased in all patients. 8